News
- Author:
- Nick Mulcahy
Publish date: September 16, 2021
In the MAGNOLIA trial, zanubrutinib “demonstrated impressive overall response and complete remission rates, with ...
News
- Author:
- Nick Mulcahy
Publish date: September 7, 2021
“Most patients with metastatic prostate cancer die from it, rather than other possible causes of death,” researcher says.
News
- Author:
- Nick Mulcahy
Publish date: September 7, 2021
The FDA stipulated that the company conduct an additional clinical trial to assess the “known serious risk of sec...
News
- Author:
- Nick Mulcahy
Publish date: September 1, 2021
The new advisory comes 4 weeks after a Medscape Medical News exclusive story on a set of clinical trials recently underway using RAS devices f...
News
- Author:
- Nick Mulcahy
Publish date: August 27, 2021
The treatment was approved for patients with von Hippel–Lindau disease undergoing treatment for renal cell carcinoma...
News
- Author:
- Nick Mulcahy
Publish date: August 13, 2021
Various oncology treatments, such as bone marrow transplantations and assorted biologics, “may leave cancer patie...
News
- Author:
- Nick Mulcahy
Publish date: August 11, 2021
Focal therapy rejects one-size-fits-all medicine in favor of individualized treatment.
News
- Author:
- Nick Mulcahy
Publish date: August 4, 2021
Physician says misleading information online may be harmful to patients.
Read More
News
- Author:
- Nick Mulcahy
Publish date: August 4, 2021
Retrospective study shows the addition of bone resorption inhibitors to abiraterone, plus prednisolone, may lengthen survival.
News
- Author:
- Nick Mulcahy
Publish date: July 28, 2021
Clinical trials are underway in the United States to explore the use of robotic surgical devices for nipple-sparing mastectomy, but investigators a...
News
- Author:
- Nick Mulcahy
Publish date: June 16, 2021
New data show that cryoablation can be an effective treatment for small, low-risk, early-stage breast cancers in ...
News
- Author:
- Nick Mulcahy
Publish date: June 10, 2021
“The survey’s recall period [about harassment] was in the previous 12 months. The respondents weren’t reflecting on a lifetime of events.”
News
- Author:
- Nick Mulcahy
Publish date: May 24, 2021
A 1-year course of adjuvant nivolumab did not negatively impact patient-reported quality of life, the trialists reported.
News
- Author:
- Nick Mulcahy
Publish date: May 6, 2021
The accelerated approval is for first-line use in combination with other agents for locally advanced unresectable or metastatic HER2-positive gastr...
News
- Author:
- Nick Mulcahy
Publish date: April 23, 2021
The accelerated approval for dostarlimab is for use in patients with recurrent or advanced endometrial cancers with deficient mismatch repair.
